Business
Weight Watchers Announces Best in Market Self-Pay Wegovy® Pricing for Med+ Members and the Launch of Preferred Subscription Pricing for Wegovy via NovoCare®
Through expanded collaboration with Novo Nordisk, eligible Med+ members can now save up to $1,200 per year on Wegovy®, increasing affordable access to FDA-approved GLP-1 treatment leveraging Weight Watchers’ integrated care platformNEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight health, today announced that eligible Weight Watchers Med+ members will have access to subscription pricing for Wegovy® tha
About this update from Novo Nordisk A/s Class B
[{"type":"image","alt":"WW International Inc.","displaySize":"","headline":null,"caption":"WW International Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/6a866065e6a3540f87dba185bc3de450"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZjpyQzAEt23gyRo3rYOuNA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc3/https://media.zenfs.com/en/globenewswire.com/6a866065e6a3540f87dba185bc3de450","width":300,"height":55}},"lazy":false},{"type":"text","content":"Through expanded collaboration with Novo Nordisk, eligible Med+ members can now save up to $1,200 per year on Wegovy®, increasing affordable access to FDA-approved GLP-1 treatment leveraging Weight Watchers’ integrated care platform","length":232,"tagName":"p"},{"type":"text","content":"NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight health, today announced that eligible Weight Watchers Med+ members will have access to subscription pricing for Wegovy® that significantly reduces out-of-pocket costs and is a result of expanded collaboration between Weight Watchers and Novo Nordisk.","length":395,"tagName":"p"},{"type":"text","content":"The new subscription offer gives Weight Watchers Med+ members access to the lowest available self-pay price in the market for doses of Wegovy not otherwise available through limited-time offers, saving cash-pay members up to $1,200 per year. The announcement coincides with Novo Nordisk’s launch of the industry’s first-of-its-kind medication subscription pricing model for Wegovy and reinforces Weight Watchers’ role as a NovoCare® Recognized Care Provider and leader in integrated, evidence-based GLP-1 care.","length":510,"tagName":"p"},{"type":"text","content":"“Novo Nordisk and Weight Watchers are each committed to helping those living with obesity take control of their health–and we are strengthening our collaboration to support that shared mission,” said Ed Cinca, Senior Vice President Marketing and Patient Solutions at Novo Nordisk. “We are making our subscription prices available to Med+ members to help them get and stay on treatment. This subscription option adds to ongoing efforts to meet people where they are, bringing transparency and predictability to those seeking treatment for obesity...